Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

Affiliations

• ¹ Division of Medical Oncology, Tumorzentrum, Luzerner Kantonsspital, Luzern, Switzerland. thilo.zander@luks.ch.
• ² Department of Medical Oncology, Inselspital, University of Bern, Bern, Switzerland.
• ³ Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.
• ⁴ Division of Medical Oncology, Tumorzentrum, Luzerner Kantonsspital, Luzern, Switzerland.
• ⁵ Oncology and Hematology, Kantonsspital Graubünden, Chur, Switzerland.
• ⁶ EOC-Istituto Oncologico della Svizzera Italiana, Ospedale San Giovanni, Bellinzona, Switzerland.
• ⁷ Department of Medical Oncology, HFR Fribourg - Hôpital cantonal, Fribourg, Switzerland.
• ⁸ Kantonsspital Winterthur, Winterthur, Switzerland.
• ⁹ Division of Hematology, Tumorzentrum, Luzerner Kantonsspital, Luzern, Switzerland.
• ¹⁰ Onkozentrum Hirslanden Zürich, Zürich, Switzerland.
• ¹¹ Department of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.